• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Suppression of sleep syncope and vagally-mediated asystole by norepinephrine transporter inhibitor.

作者信息

Rabajoli Alessandra, Raj Satish R, Sheldon Robert

机构信息

Division of Emergency Medicine and High Dependency Unit, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.

Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, Calgary, Canada.

出版信息

HeartRhythm Case Rep. 2024 Jun 20;10(9):639-643. doi: 10.1016/j.hrcr.2024.06.009. eCollection 2024 Sep.

DOI:10.1016/j.hrcr.2024.06.009
PMID:39355819
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11440121/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf2/11440121/54c03c8b9809/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf2/11440121/8abe54d7ab9f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf2/11440121/f36802d82d63/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf2/11440121/54c03c8b9809/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf2/11440121/8abe54d7ab9f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf2/11440121/f36802d82d63/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fdf2/11440121/54c03c8b9809/gr3.jpg

相似文献

1
Suppression of sleep syncope and vagally-mediated asystole by norepinephrine transporter inhibitor.去甲肾上腺素转运体抑制剂对睡眠性晕厥和迷走神经介导的心搏停止的抑制作用
HeartRhythm Case Rep. 2024 Jun 20;10(9):639-643. doi: 10.1016/j.hrcr.2024.06.009. eCollection 2024 Sep.
2
Pharmacological norepinephrine transporter inhibition for the prevention of vasovagal syncope in young and adult subjects: A systematic review and meta-analysis.药物性去甲肾上腺素转运蛋白抑制预防青年和成年患者血管迷走性晕厥的系统评价和荟萃分析。
Heart Rhythm. 2020 Jul;17(7):1151-1158. doi: 10.1016/j.hrthm.2020.02.033. Epub 2020 Mar 7.
3
A proof of principle study of atomoxetine for the prevention of vasovagal syncope: the Prevention of Syncope Trial VI.阿托西汀预防血管迷走性晕厥的原理研究：预防晕厥试验 VI。
Europace. 2019 Nov 1;21(11):1733-1741. doi: 10.1093/europace/euz250.
4
Atomoxetine for suppression of vasovagal syncope.托莫西汀抑制血管迷走性晕厥。
Clin Auton Res. 2023 Feb;33(1):23-28. doi: 10.1007/s10286-022-00905-x. Epub 2022 Nov 19.
5
Reflex vasovagal syncope--is there a benefit in pacemaker therapy?反射性血管迷走性晕厥——起搏器治疗有获益吗？
Rev Port Cardiol. 2014 May;33(5):297-303. doi: 10.1016/j.repc.2014.02.007. Epub 2014 Jun 2.
6
Management and therapy of vasovagal syncope: A review.血管迷走性晕厥的管理与治疗：综述
World J Cardiol. 2010 Oct 26;2(10):308-15. doi: 10.4330/wjc.v2.i10.308.
7
The Seventh Prevention of Syncope Trial (POST VII)-A randomized clinical trial of atomoxetine for the prevention of vasovagal syncope: Rationale and study design.第七次晕厥预防试验（POST VII）-托莫西汀预防血管迷走性晕厥的随机临床试验：原理和研究设计。
Am Heart J. 2023 Aug;262:49-54. doi: 10.1016/j.ahj.2023.04.012. Epub 2023 Apr 24.
8
Severe cardioinhibitory vasovagal syncope in sleep and supine posture.睡眠及仰卧位时的严重心脏抑制型血管迷走性晕厥
Epileptic Disord. 2014 Mar;16(1):101-6. doi: 10.1684/epd.2014.0627.
9
Prevalence of asystole during tilt test-induced vasovagal syncope may depend on test methodology.倾斜试验诱发血管迷走性晕厥期间出现心搏停止的发生率可能取决于试验方法。
Europace. 2023 Feb 16;25(2):263-269. doi: 10.1093/europace/euac154.
10
Atomoxetine as an adjunct to nonpharmacological treatments for preventing vasovagal attacks in patients with recurrent vasovagal syncope: A pilot randomized-controlled trial.托莫西汀作为预防复发性血管迷走性晕厥患者血管迷走性发作的非药物治疗辅助手段：一项前瞻性随机对照试验。
Int J Cardiol Heart Vasc. 2021 May 8;34:100789. doi: 10.1016/j.ijcha.2021.100789. eCollection 2021 Jun.

本文引用的文献

1
The Seventh Prevention of Syncope Trial (POST VII)-A randomized clinical trial of atomoxetine for the prevention of vasovagal syncope: Rationale and study design.第七次晕厥预防试验（POST VII）-托莫西汀预防血管迷走性晕厥的随机临床试验：原理和研究设计。
Am Heart J. 2023 Aug;262:49-54. doi: 10.1016/j.ahj.2023.04.012. Epub 2023 Apr 24.
2
Atomoxetine for suppression of vasovagal syncope.托莫西汀抑制血管迷走性晕厥。
Clin Auton Res. 2023 Feb;33(1):23-28. doi: 10.1007/s10286-022-00905-x. Epub 2022 Nov 19.
3
Midodrine for the prevention of vasovagal syncope: a systematic review and meta-analysis.
米多君预防血管迷走性晕厥的疗效：系统评价和荟萃分析。
Europace. 2022 Jul 21;24(7):1171-1178. doi: 10.1093/europace/euab323.
4
Sleep syncope: a prospective cohort study.睡眠性晕厥：一项前瞻性队列研究。
Clin Auton Res. 2022 Feb;32(1):19-27. doi: 10.1007/s10286-021-00842-1. Epub 2022 Jan 7.
5
The pathophysiology of vasovagal syncope: Novel insights.血管迷走性晕厥的病理生理学：新的见解。
Auton Neurosci. 2021 Dec;236:102899. doi: 10.1016/j.autneu.2021.102899. Epub 2021 Oct 18.
6
Pharmacological norepinephrine transporter inhibition for the prevention of vasovagal syncope in young and adult subjects: A systematic review and meta-analysis.药物性去甲肾上腺素转运蛋白抑制预防青年和成年患者血管迷走性晕厥的系统评价和荟萃分析。
Heart Rhythm. 2020 Jul;17(7):1151-1158. doi: 10.1016/j.hrthm.2020.02.033. Epub 2020 Mar 7.
7
A proof of principle study of atomoxetine for the prevention of vasovagal syncope: the Prevention of Syncope Trial VI.阿托西汀预防血管迷走性晕厥的原理研究：预防晕厥试验 VI。
Europace. 2019 Nov 1;21(11):1733-1741. doi: 10.1093/europace/euz250.
8
Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial.氟氢可的松预防血管迷走性晕厥的随机、安慰剂对照试验。
J Am Coll Cardiol. 2016 Jul 5;68(1):1-9. doi: 10.1016/j.jacc.2016.04.030.
9
Norepinephrine transporter function and human cardiovascular disease.去甲肾上腺素转运蛋白功能与人类心血管疾病。
Am J Physiol Heart Circ Physiol. 2012 Dec 1;303(11):H1273-82. doi: 10.1152/ajpheart.00492.2012. Epub 2012 Sep 28.
10
Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation.去甲肾上腺素转运体抑制改变对超重力的血流动力学反应。
J Appl Physiol (1985). 2008 Mar;104(3):756-60. doi: 10.1152/japplphysiol.01128.2007. Epub 2008 Jan 10.